Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Biocryst Pharmaceuticals Inc.
Headquarters: Durham, NC, United States of America
Website: http://www.biocryst.com
Year Founded: 1986
Status: Public
Industry Sector: HealthTechnology
CEO: Jon P. Stonehouse
Number Of Employees: 580
Enterprise Value: $2,074,711,920
PE Ratio: -17.04
Exchange/Ticker 1: NASDAQ:BCRX
Exchange/Ticker 2: N/A
Latest Market Cap: $1,531,676,800
BioCentury | Mar 5, 2025
Management Tracks
CFO Anthony Doyle resigns at Biocryst
Plus: Greenside succeeds CEO Mark DePristo at Bighat, and updates from Be Biopharma, 3t and Imugene
BioCentury | Mar 31, 2023
Management Tracks
Amarin CEO Mikhail resigns, Kostas named chair
Plus: BioCryst appoints Hutson chair and updates from Flare, Mytide and TScan
BioCentury | Dec 16, 2022
Finance
Dec. 15 Quick Takes: Enlaza debuts with $61M, covalent targeting biologics platform
Plus: MinervaX taking strep vaccine to Phase II and updates from AbbVie, Prothena, Astria, Guardant and more
BioCentury | Sep 17, 2022
Product Development
HAE data clear Intellia’s path for liver knockout indications
The next test for Intellia will be whether it can achieve the same success with gene insertions
BioCentury | Sep 15, 2022
Management Tracks
New roles for Sheridan, Arnold at BioCryst
Plus Maltais joins XNK as CSO, and updates from HaYa, Ratio and more
BioCentury | Aug 16, 2022
Management Tracks
Simcha hires CEO, expands research agreement
Plus Integra’s Caruso passes away and updates from Ambrx, Cullinan, Zephyr, South Rampart and more
BioCentury | Aug 5, 2022
Finance
Aug. 4 Quick Takes: Forbion, Sofinnova lead F2G’s $70M financing
Plus newco emerges from Daley lab and updates Lilly, Pfizer, Regeneron, Arucs-Gilead, Travere, BioCryst and more
BioCentury | Apr 9, 2022
Finance
April 8 Quick Takes: Kaleido winding down operations
Plus: BioCryst loses $1.2B in market cap after pivotal pause and the latest in CEPI investments and more
BioCentury | Dec 3, 2021
Management Tracks
Sniecinski becomes CBO at Praxis
Plus: Monte Rosa, Taro, Point, Harbour and more
BioCentury | Nov 23, 2021
Product Development
Nov. 22 Quick Takes: GSK, Arrowhead in deal for NASH candidate
Plus Zenas-Xencor, BioCryst, Deciphera, bluebird, Exelixis and more
Items per page:
1 - 10 of 375